New perspectives on Alzheimer's disease from neuroimaging;Neuroimagen en la enfermedad de Alzheimer: Nuevas perspectivas

Revista de Neurologia

Volumn 50, Issue SUPPL. 5, 2010, Pages

  Becker, James T ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Alzheimer's disease; Cardiovascular disease; Cerebrovascular disease; Magnetic resonance imaging; Neuroimaging

Indexed keywords

ADULT; ALZHEIMER DISEASE; ARTICLE; CLINICAL FEATURE; DEMENTIA; HUMAN; NEUROIMAGING;

AGED; ALZHEIMER DISEASE; BRAIN; DEMENTIA; DIAGNOSTIC IMAGING; HUMANS;

EID: 77953557590     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337-42. (Pubitemid 28402270)
2. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002; 72: 310-4.
3. Lopez OL, Becker JT, Saxton J, Sweet R, Klunk W, DeKosky ST. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc 2005; 53: 83-7. (Pubitemid 41647636)
4. Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009; 80: 600-7.
5. Tárraga L, Boada M, Modinos G, Espinosa A, Diego S, Morera A, et al. A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2006; 77: 1116-21. (Pubitemid 44453244)
6. Resnick NM, Marcantonio ER. How should clinical care of the aged differ? Lancet 1997; 350: 1157-8.
7. Satz P. Brain reserve capacity on symptom onset after brain injury: a formulation and review of evidence of threshold theory. Neuropsychology 1991; 7: 273-95.
8. Stern Y, Alexander GE, Prohovnik I, Stricks L, Link B, Lennon MC, et al. Relationship between lifetime occupation and parietal flow: implications for a reserve against Alzheimer's disease pathology. Neurology 1995; 44: 55-60.
9. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000; 21: 49-55. (Pubitemid 30224785)
10. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347-51.
11. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65: 1509-17.
12. Raji CA, Lopez OL, Kuller LH, Carmichael OT, Becker JT. Age, Alzheimer disease, and brain structure. Neurology 2009; 73: 1899-905.
13. Good CD, Johnsrude IS, Ashburner J, Henson RNA, Friston KJ, Frackowiak RSJ. A voxel-based morphometric study of aging in 465 normal adult human beings. Neuroimage 2001; 14 (Pt 1): 21-36.
14. Junqué C, Pujol J, Vendrell P, Bruna O, Jódar M, Ribas JC, et al. Leuko-araiosis on magnetic resonance imaging and speed of mental processing. Arch Neurol 1990; 47: 151-6. (Pubitemid 20058110)
15. Breteler MM, Van Swieten JC, Bots ML, Grobbee DE, Claus JJ, Van den Hout JH, et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. Neurology 1994; 44: 1246-52.
16. Grafton ST, Sumi SM, Stimac GK, Alvord EC, Shaw C, Nochlin D. Comparison of postmortem magnetic resonance imaging and neuropathologic findings in the cerebral white matter. Arch Neurol 1991; 48: 293-8.
17. Kobari M, Meyer JS, Ichijo M, Oravez WT. Leukoaraiosis: correlation of MR and CT findings with blood flow, atrophy, and cognition. AJNR Am J Neuroradiol 1990; 11: 273-81.
18. Scheltens P, Barkhof F, Leys D, Wolters E, Ravid R, Kamphorst W. Histopathologic correlates of white matter changes on MRI in Alzheimer's disease. Neurology 1995; 45: 883-8.
19. Hall AM, Moore RY, Lopez OL, Kuller LH, Becker JT. Basal forebrain atrophy is a presymptomatic marker for Alzheimer's disease. Alzheimers Dement 2008; 4: 271-9.
20. Raji CA, Ho AJ, Parikshak NN, Becker JT, Lopez OL, Kuller LH, et al. Brain structure and obesity. Hum Brain Mapp 2009; Aug 6 [Epub ahead of print].
21. Hua X, Leow AD, Parikshak N, Lee S, Chiang MC, Toga AW, et al; Alzheimer's Disease Neuroimaging Initiative. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage 2008; 43: 458-69.
22. Dai W, Lopez OL, Carmichael OT, Becker JT, Kuller L, Gach HM. Mild cognitive impairment and Alzheimer disease: patterns of altered cerebral blood flow at MR imaging. Radiology 2009; 250: 856-66.
23. Dai W, Lopez OL, Carmichael OT, Becker JT, Kuller LH, Gach HM. Abnormal regional cerebral blood flow in cognitively normal elderly subjects with hypertension. Stroke 2008; 39: 349-54. (Pubitemid 351619454)